In Vitro Functional Validation of an Anti-FREM2 Nanobody for Glioblastoma Cell Targeting.

ABSTRACT: Background/Objectives: Glioblastomas are the most common brain malignancies. Despite the implementation of multimodal therapy, patient life expectancy after diagnosis is barely 12 to 18 months. Glioblastomas are highly heterogeneous at the genetic and epigenetic level and comprise multiple different cell subpopulations. Therefore, small molecules such as nanobodies, able to target membrane proteins specific to glioblastoma cells or specific cell types within the tumor are being investigated as novel tools to treat glioblastomas. Methods: Here, we describe the identification of such a nanobody and its in silico and in vitro validation. NB3F18, as we named it, is directed against the membrane-associated protein FREM2, overexpressed in glioblastoma stem cells. Results: Th

SUBMITTER: Krapez G 

PROVIDER: S-EPMC11843905 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature